Towards greener patents and innovations: Is your IPR strategy aligned with your sustainability goals?

Posted on

23 Nov


Dittmar & Indrenius > Insight > Towards greener patents and innovations: Is your IPR strategy aligned with your sustainability goals?
Sustainability is part of the strategy of every active company, irrespective of their business area. However, sustainability is not a new concept. Despite being a buzzword in 2020 and 2021, sustainable development has been a fundamental objective of the European Union since 1997, when it was included in the Treaty of Amsterdam as an overarching objective of EU policies.  

Similarly, the promotion of innovation has also been a key driver in reaching the EU’s primary role in the digital and green economy. One specific area where innovation has been addressed on a European level is the field of Intellectual Property Rights (IPRs) and in the specification and harmonisation of its protection and enforcement. For example, the European Commission itself recognises the need to have uniform legislation in EU Patent protection rules: “Patents are a key tool to encourage investment in innovation and encourage its dissemination. The European Commission constantly monitors the need for and effects of patent-related legislation across the EU.”[1]

Seeing that these two concepts (i.e. sustainability and innovation) are at the core of the European Union’s goals and objectives, why is it so hard to find their connection? The answer may be obvious: it is because they are not (currently) being considered as part of the same package. But, can private stakeholders do more to integrate sustainability in their IPR strategy?

We are currently witnessing a tendency to integrate companies’ ESG commitments[2] in their contracts and policies. In the field of IPRs, we have seen the need to draft contractual clauses to deal with climate technology (for example, know-how or technologies relating to climate change) and their respective licensing terms. However, this niche area is currently underexplored.

[1] Patent protection in the EU | Internal Market, Industry, Entrepreneurship and SMEs (

[2] ESG stands for “Environmental, social and corporate governance”.

We believe that one area where the intersection of both sustainability and innovation can reach a positive outcome is in the field of patents and life sciences innovations.

We believe that one area where the intersection of both sustainability and innovation can reach a positive outcome is in the field of patents and life sciences innovations. Yet, there is still much to be done both in terms of environmental and social sustainability. Currently, under the European Patent Convention (EPC), “European patents shall be granted for any inventions, in all fields of technology, provided that they are new, involve an inventive step and are susceptible of industrial application.[3]” However, there some specific exceptions to patentability and one of them is ordre publicconsiderations or morality.[4] A similar exception affecting the life sciences field can be found from Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions (the “Biotech Patent Directive”). Interestingly, the EPC does not mention “sustainability” but the Biotech Patent Directive refers to the “sustainable use of biological diversity“.

The (negative) exception mechanism is evidently inappropriate to deal with sustainability considerations, mainly because its ultimate goal is to deny protection to inventions that fall under the exceptions. Conversely, positive, new incentive mechanisms could foster innovation and promote sustainability in areas such as climate change or life sciences. For example, some countries have set up a “fast-track” system for green patents where the time from application to granting of a patent can be significantly reduced. When countries throughout the world are considering what actions are available to reach the Paris Agreement climate goals, this should be an option on the table.

For companies, there is a multitude of tools that can be used to promote sustainability through a (rewarding) IPR strategy. For example, from the angle of employee inventions, there is room to create a reward system that would encourage employees to innovate and propose solutions that would help the company reach their own sustainability goals. Similarly, if a company would get, for example, a financial benefit for filing a green patent, this could increase the invention rate in this field and encourage companies to play their own role in climate change mitigation and adaptation.

The world is shifting to a time where companies and governments are being held liable for climate change inaction and/or for their impact on climate. The time for action is now and the discussion has been launched. Let’s think green, think ahead, discuss and act together.

[3] EPC Article 52(1).

[4] EPC Article 53.

More by the same author

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

The European Parliament and the Council reach an agreement on European Health Data Space!

Towards a stronger European Health Union On March 15, 2024, the European Parliament and the Belgian Presidency of the Council reached a provisional political agreement on the European Health Data Space (EHDS) which is considered one of the central building blocks towards a stronger European Health Union. The upcoming EHDS aims to harness the full potential offered by the sharing, use, and re-use of health data, while ensuring full compliance with the data protection standards in the EU. This marks a significant milestone in the EU’s health data regulation.

Commission proposes extension of IVDR transition periods for legacy products

The European Commission has on 23 January 2024 announced a proposal for an extension to the transition period for the forthcoming In Vitro Diagnostic Medical Devices Regulation (IVDR). The aim is to ensure patient care by improving the availability of these essential healthcare products. In addition, the Commission also proposes measures to enable and accelerate a gradual roll out of EUDAMED, a database that will contain information about all medical devices and in vitro diagnostics (IVDs) placed on the EU market. The mandatory use of finalised parts of EUDAMED will support all key players in the implementation of the regulatory framework and enhance transparency for the public.

Latest insights

Draft New Act Governing Offshore Wind Power within the Finnish EEZ Published for Comments

Alert / 28 May 2024
Reading time 2 minutes

Government proposal regarding the implementation of EU’s NIS 2 Directive published

Alert / 24 May 2024
Reading time 2 minutes